Literature DB >> 20335784

IgA nephropathy associated with Castleman disease with cutaneous involvement.

Atsushi Komatsuda1, Hideki Wakui, Masaru Togashi, Ken-Ichi Sawada.   

Abstract

A 35-year-old Japanese man developed systemic lymphadenopathy during the course of immunosuppressive therapy for IgA nephropathy associated with cutaneous nodules, polyclonal hypergammaglobulinemia, and persistent increased serum C-reactive protein of unknown cause. Lymph node examination showed the plasmacytic type of Castleman disease (CD). A skin biopsy showed specific pathologic findings of CD cutaneous involvement. Considering the involvement of interleukin-6 in CD, we treated the patient with humanized anti-interleukin-6 receptor antibody. Thereafter, his symptoms and abnormal laboratory findings were improved. Cutaneous CD has rarely been described in Asian population, and renal complications in CD are uncommon and heterogeneous. To our knowledge, this is the first case of IgA nephropathy associated with multicentric CD with cutaneous involvement.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335784     DOI: 10.1097/MAJ.0b013e3181da4321

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  8 in total

Review 1.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

Review 2.  "Coexistence of IgA nephropathy and renal artery stenosis in Takayasu arteritis: case report and literature review".

Authors:  Nono Ito; Tsuyoshi Shirai; Takafumi Toyohara; Hideaki Hashimoto; Hiroko Sato; Hiroshi Fujii; Tomonori Ishii; Hideo Harigae
Journal:  Rheumatol Int       Date:  2022-01-11       Impact factor: 2.631

3.  Interleukin-6 Downregulates the Expression of Vascular Endothelial-Cadherin and Increases Permeability in Renal Glomerular Endothelial Cells via the Trans-Signaling Pathway.

Authors:  Yong-Chang Yang; Hui Fu; Bo Zhang; Yu-Bin Wu
Journal:  Inflammation       Date:  2022-07-23       Impact factor: 4.657

4.  Castleman disease mimicked pancreatic carcinoma: report of two cases.

Authors:  Hua Guo; Yan Shen; Wei-Lin Wang; Min Zhang; Hong Li; Ying-Sheng Wu; Sheng Yan; Xiao Xu; Jian Wu; Shu-Sen Zheng
Journal:  World J Surg Oncol       Date:  2012-07-23       Impact factor: 2.754

5.  The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome.

Authors:  Masatoshi Matsunami; Yoshifumi Ubara; Keiichi Sumida; Yoichi Oshima; Masahiko Oguro; Kazuya Kinoshita; Kiho Tanaka; Yuki Nakamura; Keiichi Kinowaki; Kenichi Ohashi; Takeshi Fujii; Takuro Igawa; Yasuharu Sato; Yasuo Ishii
Journal:  BMC Nephrol       Date:  2018-10-11       Impact factor: 2.388

6.  The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease.

Authors:  Ikuko Kubokawa; Akihiro Yachie; Akira Hayakawa; Satoshi Hirase; Nobuyuki Yamamoto; Takeshi Mori; Tomoko Yanai; Yasuhiro Takeshima; Eiryu Kyo; Goichi Kageyama; Hiroshi Nagai; Keiichiro Uehara; Masaru Kojima; Kazumoto Iijima
Journal:  BMC Pediatr       Date:  2014-06-02       Impact factor: 2.125

7.  Rare Forms of Castleman Disease Mimicking Malignancy: Mesenteric and Pancreatic Involvement.

Authors:  Mustafa Ozsoy; Zehra Ozsoy; Suleyman Sahin; Yuksel Arıkan
Journal:  Cureus       Date:  2018-03-12

8.  Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report.

Authors:  Ping-Yang Han; Hui-Hui Chi; Yu-Tong Su
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.